FIELD: pharmacology.
SUBSTANCE: invention relates to the use of oreganol A as a drug with neurotropic activity for the treatment of neurosis and psychosis.
EFFECT: invention makes it possible to increase the effectiveness of the therapeutic effect and exclude the occurrence of side effects.
9 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF SALICIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832938C1 |
| USE OF CYNAROSIDE HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832839C1 |
| USE OF ISORHAMNETIN 3-O-β-D-GLUCOPYRANOSIDE, HAVING NEUROTROPIC ACTIVITY | 2024 |
|
RU2833215C1 |
| USE OF APIGENIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832841C1 |
| USE OF COSMOSIIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2833214C1 |
| USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
| USE OF GAULTERIN AS ANTIDEPRESSANT | 2023 |
|
RU2825385C1 |
| USE OF OREGANOL A WITH DIURETIC ACTIVITY | 2022 |
|
RU2802873C1 |
| USE OF QUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802833C1 |
| USE OF DIHYDROQUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802874C1 |
